Plasma protein binding

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Wednesday, November 15, 2023
CNS, Sale, CSMC, Retina, Patient, Triple-negative breast cancer, Attention deficit hyperactivity disorder, Cayman, Investigational New Drug, US FDA, Licensed production, Cancer, Power purchase agreement, SIV, Security (finance), Toxicity, Plasma protein binding, Syndrome, IND, Surgeon, TGA, BioLite, ADHD, Taiwan Stock Exchange, Sales management, Hydrogel, MDD, Pancreatic cancer, Depression, GMP, Good manufacturing practice, Bank statement, UCSF, MDS, University, Partnership, Phase, Drug development, Research, ANDA, Warrant, FDA, Dietary supplement, West Pharmaceutical Services, Share (finance), Pharmaceutical industry, Cryptocurrency, Qiu Zhonghui

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.

Key Points: 
  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.
  • During July 2023, the warrant exercise price was reset to $3.5 under the issuance of common stock about securities purchase agreement on July 2023.
  • During the third quarter of 2023, the Company issued to Zhonghui an aggregate of 370,000 shares of the Company's common stock at a per-share price of $20.
  • "We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma.

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Drug development, Disease, NESS, Safety, NYSE, Policy, Senior, Food, Cystic fibrosis, Plasma protein binding, H.262/MPEG-2 Part 2, Workforce, Sputum, Clinical trial, Mortality, Insurance, Patient, Research, Part, FDA, Pharmacokinetics, Bacteria, Novartis, Conference, Pseudomonas aeruginosa, FEV1, Communication, CFU, Dermatology, Physician, Psoriatic arthritis, Fast Track, Part Two, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.

Key Points: 
  • and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.
  • In addition, the U.S. Food and Drug Administration recently granted Fast Track designation for BX004, further underscoring the potential of this promising program.
  • Net loss for the third quarter of 2023 was $7.9 million, compared to $6.8 million for the same period in 2022.
  • Net cash used in operating activities for the nine months ended September 30, 2023, was $15.0 million, compared to $21.9 million for the same period in 2022.

United States Health Insurance Market Analysis Report 2023: A $1,639 Billion Industry by 2028 from $1,150 Billion in 2022 - Competition, Forecasts and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Health, Health Insurance, Preferred provider organization, United States Census Bureau, Medicaid, Conditional sentence, Affordable Care Act, Prevalence, California Insurance Commissioner, International Diabetes Federation, Cardiovascular disease, Insurance, Elevance Health, Patient, National Association, USD, Telehealth, Health maintenance organization, NAIC, COVID-19, ACA, Cancer, Plasma protein binding, POS, Growth, Hospital, Diabetes, DSM-IV codes, Trump, Health insurance, Cigna

The "United States Health Insurance Market Competition, Forecast and Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Health Insurance Market Competition, Forecast and Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.
  • United States health insurance market is expected to reach a value of $1639.44 billion by 2028, up from $1150.23 billion in 2022, driven by the increasing private health insurance provider and rising medical expenditures during the forecast period.
  • The United States health insurance market has experienced significant growth over the past decade, driven by several factors, such as rising healthcare costs, increasing awareness of health insurance, and a surging population.
  • The United States offers ample opportunities for health insurance companies to expand their offerings beyond traditional health insurance products.

Medefy Health Raises $10 million Series A Funding to Deliver Real-Time Healthcare Benefits Navigation through Human-Led Support

Retrieved on: 
Monday, December 11, 2023
Health Technology, Health Insurance, Technology, Human Resources, Pharmaceutical, Apps, Applications, Professional Services, General Health, Clinical Trials, Science, Biotechnology, Other Science, Health, Mobile, Wireless, Research, Organization, Entrepreneurship, Risk, Insurance, Patient, Rest, Intelligence, TPA, App Store (iOS/iPadOS), U.S. Venture Partners, Mercury, Plasma protein binding, Growth, App, Health insurance

Medefy Health, a mobile-first healthcare benefits navigation platform dedicated to improving the employee health benefits experience through real-time guidance, today announced that it has raised $10 million in Series A funding led by Mercury Fund with participation from Advantage Capital.

Key Points: 
  • Medefy Health, a mobile-first healthcare benefits navigation platform dedicated to improving the employee health benefits experience through real-time guidance, today announced that it has raised $10 million in Series A funding led by Mercury Fund with participation from Advantage Capital.
  • The new funding will enable Medefy to further enhance its existing technology platform and artificial intelligence capabilities to operate more efficiently at scale.
  • The platform also centralizes the company’s overall health plan into one mobile experience, driving more member usage of other vendors, benefits, and programs.
  • Medefy is providing a centralized benefits navigation solution that delivers expert guidance, reduces costs, and improves price transparency.

Global Proteomics Strategic Research Report 2023: Growing Interest in Personalized Medicine to Drive Market Growth - Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 6, 2023
Biotechnology, General Health, Pharmaceutical, Health, Medicine, Proteome, Protein, Growth, Vaccine, COVID-19, Plasma protein binding, Therapy, Drug discovery, Biology, Proteomics

The "Proteomics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Proteomics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • Growth in the Instruments segment is estimated at 11% CAGR for the next 8-year period.
  • The global proteomics market is competitive, with various key competitors vying for market share, and their competitive presence varies from strong to niche or trivial.
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Global CNS Therapeutics Strategic Research Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 1, 2023
General Health, Health, Other Health, CNS, Neurodegenerative disease, Pressure, Research, Therapy, Pathology, Incidence, Patient, Growth, Mental health, BBB, Music, Alzheimer's disease, Dementia, Epilepsy, Plasma protein binding, Biology, Traffic barrier, Central nervous system, Pharmaceutical industry, Pet industry, Video game

The "CNS Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CNS Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global CNS (Central Nervous System) therapeutics market is witnessing significant growth due to various factors.
  • Moreover, increased spending on prescription drugs and rising healthcare expenditure are contributing to the expansion of the CNS therapeutics market.
  • Despite the complexities of research and development in this field, the future outlook for CNS therapeutics appears promising, with novel drug-delivery options and advances in drug discovery methods for rare diseases.

Polyphenol Market Global Industry Trends and Forecast Report 2023-2028 - Widespread Product Utilization in the Food and Beverage Industry is Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Food, Beverage, Retail, Research, Beer, Polyphenol, Seed, F&B, Lipid, Eye, Health, Cancer, Plasma protein binding, R, Allergy, Diabetes, Catechin, Dietary supplement

The widespread product utilization in the food and beverage (F&B) industry is driving the market growth.

Key Points: 
  • The widespread product utilization in the food and beverage (F&B) industry is driving the market growth.
  • Additionally, the increasing product demand due to its effectiveness in treating cardiovascular conditions, skin allergies, and eye diseases resulting from diabetes and cancer is favoring the market growth.
  • The report provides an analysis of the key trends in each sub-segment of the global polyphenol market report, along with forecasts at the global, regional and country level from 2023-2028.
  • The report has categorized the market based on source, product type, type, form and application.

FDA Grants Fast Track Designation to SonALAsense’s SONALA-001 in Combination with the INSIGHTEC Transcranial Ultrasound Device for Sonodynamic Therapy of DIPG, a Rare Pediatric Brain Cancer

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Health, FDA, Medical Devices, Neurology, Clinical Trials, Biotechnology, Brain, SDT, Safety, Annual general meeting, Radiation, ALA, Pons, Pakistan Society of Neuro-Oncology, Plasma protein binding, Collection, Sonodynamic therapy, Patient, Heart rate, Light, NCT, Hydrogen chloride, Diffuse intrinsic pontine glioma, Survival, Diagnosis, Trial of the century, Communication, Biomarker, DIPG, SNO, Spinal cord, Blood pressure, Pharmaceutical industry, Development

This builds upon SONALA-001 also having received orphan drug designation in 2021 for malignant gliomas.

Key Points: 
  • This builds upon SONALA-001 also having received orphan drug designation in 2021 for malignant gliomas.
  • The FDA’s Fast Track is a process designed to facilitate the development, and expedited review, of drugs to treat serious conditions and fill an unmet medical need.
  • “Receiving Fast Track Designation underscores the immediate and urgent need to bring new therapy options for DIPG patients,” said Ely Benaim, M.D., SonALAsense’s Chief Medical Officer and Executive Vice President of Development.
  • Approximately 300 children are diagnosed with DIPG each year in the US, usually between the ages of 5 and 9.

Public advisory - Unauthorized injectable drug products sold online by Canlab Research may pose serious health risks

Retrieved on: 
Wednesday, December 13, 2023
Sale, Peptide, Infant, Abdominal pain, Headache, Triptorelin, Patient, Oxytocin, Ovulation, Water intoxication, Pharyngitis, Infection, Oxygen, Background, Amniotic fluid, Erectile dysfunction, Lethargy, Pharmacy, Vomiting, Placenta, Osteoporosis, Safety, Fertility, Argyreia nervosa, Asphyxia, Canada Border Services Agency, DIN, Pelvimetry, Uterine rupture, Nursing, Drug identification number, Toxemia, Health, Diarrhea, Bleeding, Health Canada, Nausea, Chronic pain, Plasma protein binding, Fetus, Allergy, Somnolence, Anaphylaxis, Endometriosis, Depression, Hormone, Risk, Constipation, History, Premature, Long QT syndrome, Stroke, Seizure, Pain, Natural product, Drug, Upper respiratory tract infection, NPN, Prostate cancer, Prescription drug, Pituitary gland, Dietary supplement

Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.

Key Points: 
  • Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.
  • The products are promoted as peptides and are sold online via Canlab Research websites including www.canlabresearch.com and www.canlab.net .
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • This is not a complete description of all the unauthorized health products advertised and sold on the Canlab Research websites.

PMPRB release analyzes key cost pressures driving changes in public plan prescription drug expenditures

Retrieved on: 
Tuesday, December 12, 2023
Plasma protein binding, Disease, Growth, Annual report, PMPRB, Policy, Pharmaceutical industry

CompassRx provides insight into the factors driving prescription drug expenditures in select Canadian public drug plans.

Key Points: 
  • CompassRx provides insight into the factors driving prescription drug expenditures in select Canadian public drug plans.
  • Prescription drug expenditures for the NPDUIS public drug plans increased by 6.8% in 2021-22, bringing annual spending to $13.2 billion.
  • Total prescription drug expenditures for Canada's public drug plans rose by $3.1 billion over the last 5 years, for a compound annual growth rate of 4.9%.
  • Drug costs in NPDUIS public plans grew by 8.4% in 2021-22, accounting for $10.9 billion of a total $13.2 billion in public drug plan expenditures, while dispensing costs had a modest growth (0.1% or $1.7 million).